Related Experiment Video
Updated: Feb 10, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma
Shigeo Godo1,2, Yoshitaro Yoshida2, Naoki Kawamorita3
1Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan.
Abstract:
Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia. An abundance of caution for unusual and unpredictable toxicities is warranted when using axitinib.
Insights
Axitinib is a cancer drug for advanced kidney cancer. While generally safe, this case highlights a rare but severe risk of life-threatening hyperkalemia, requiring careful patient monitoring.
Area of Science:
- Oncology
- Pharmacology
- Nephrology
Background:
- Axitinib is an antineoplastic agent used for advanced renal cell carcinoma.
- Clinical trials suggest good tolerability, but real-world safety data is limited.
Observation:
- A patient with metastatic renal cell carcinoma developed severe, life-threatening hyperkalemia after starting axitinib.
- This adverse event occurred despite axitinib generally being well-tolerated in trials.
Findings:
- Hyperkalemia is a known, albeit infrequent (<10%), side effect of axitinib.
- Severe acute hyperkalemia represents a critical, potentially life-threatening adverse event, particularly in at-risk patients.
Implications:
- Real-world data indicates axitinib can cause severe hyperkalemia, a critical toxicity.
- Physicians should exercise caution for unpredictable toxicities and monitor patients closely for hyperkalemia during axitinib treatment.
- Risk stratification for hyperkalemia is crucial in patients undergoing axitinib therapy for renal cell carcinoma.
More Related Videos
Related Concept Videos
02:42Half-life of a Reaction
01:23Characteristics of Life
02:39The Angiosperm Life Cycle
02:40The Tree of Life - Bacteria, Archaea, Eukaryotes
01:22Life Tables
01:29Life Histories